Article

Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug Combination

2021-10-23

Abstract excerpt

Non-small cell lung cancer (NSCLC) is commonly diagnosed at advanced stages limiting treatment options. Although, targeted therapy has become integral part of NSCLC treatment therapies often fail to improve patient’s prognosis. Based on previously published criteria for selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft (PDX) tumors were treated with a low dose combination of c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ac700c83-ccd7-564a-8a37-af96c1796490
DOI: 10.1101/2021.10.23.465545

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug CombinationDOI 10.1101/2021.10.23.465545Read

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.Semantic proximity Read

Molecular principles underlying aggressive cancersSemantic proximity Read

Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.Semantic proximity Read

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patientsSemantic proximity Read

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung CancerSemantic proximity Read

Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidenceSemantic proximity Read

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker GenesSemantic proximity Read

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Semantic proximity Read

Activation of NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung CancerSemantic proximity Read

Pathological transition as the arising mechanism for drug resistance in lung cancerSemantic proximity Read

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients.Semantic proximity Read